Muhlenkamp & CO Inc Biogen Inc. Transaction History

Muhlenkamp & CO Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Dec 10, 2021	SELL	$282.99 - $369.05 $5.16 Million - $6.72 Million	-18,218 Closed	0 $0
Q2 2021 Aug 18, 2021	BUY	$259.0 - $414.71 $8,806 - $14,100	34 Added 0.19%	18,218 $6.31 Million
Q1 2021 Aug 18, 2021	BUY	$242.95 - $284.63 $8,989 - $10,531	37 Added 0.2%	18,184 $6.36 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $22,208 - $33,429	94 Added 0.52%	18,147 $4.44 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $58,778 - $67,867	222 Added 1.25%	18,053 $5.12 Million
Q2 2020 Aug 20, 2020	BUY	$258.66 - $342.55 $16,295 - $21,580	63 Added 0.35%	17,831 $4.77 Million
Q4 2019 Feb 20, 2020	SELL	$220.06 - $304.07 $1,320 - $1,824	-6 Reduced 0.03%	17,768 $5.27 Million
Q3 2019 Nov 27, 2019	SELL	$217.44 - $243.88 $1,304 - $1,463	-6 Reduced 0.03%	17,774 $4.14 Million
Q2 2019 Aug 28, 2019	SELL	$219.29 - $241.72 $13,815 - $15,228	-63 Reduced 0.35%	17,780 $4.16 Million
Q1 2019 May 23, 2019	SELL	$216.71 - $338.96 $113,772 - $177,954	-525 Reduced 2.86%	17,843 $4.22 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $2 Million - $2.61 Million	-6,803 Reduced 27.03%	18,368 $6.49 Million
Q1 2018 May 11, 2018	BUY	$260.13 - $367.91 $127,203 - $179,907	489 Added 1.98%	25,171 $0
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $41,531 - $46,518	135 Added 0.55%	24,682 $7.86 Million
Q3 2017 Nov 13, 2017	SELL	$281.15 - $329.69 $280,587 - $329,030	-998 Reduced 3.91%	24,547 $7.69 Million
Q2 2017 Aug 11, 2017	BUY	N/A	25,545	25,545 $6.93 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Muhlenkamp & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Muhlenkamp & CO Inc with notifications on news.